Tenax Therapeutics, Inc.

NASDAQ:TENX

Biotechnology

Healthcare
$1.91 +0.88%

+$0.10 today

Market cap
$50.66M
Beta
0.97
P/E (TTM)
-9.4
EPS (TTM)
-$1.28
52W Low $5.34High $18.38

Volume 0.70M

Average 0.62M

TENX Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Tenax Therapeutics, Inc.NASDAQ: TENX

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses grows, but more slowly than its trailing trend

Q1 FY2026 operating expenses of $16.57M rose 46.2% year over year, behind the +248.4% change in trailing-twelve-month operating expenses. Sequentially, it rose 0.8% from the prior quarter. Over 3 fiscal years it compounded at +72.1% a year.

Context

  • Operating expenses increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +46.2% toward the trailing-twelve-month pace of +248.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$16.57M+0.8% QoQ
Last fiscal yearDec 2025
$56.39M+189.2% YoY
LTMMar 2026
$61.62M+248.4% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+46.2%——
1 year+189.2%——
3-year CAGR+72.1%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
56.39M USD
Year-over-year change
+189.2%
4-year CAGR
+14.6%

Operating Expenses vs competitors

How TENX compares with its peers on the latest reported figures

  • TENX's LTM Mar 2026 operating expenses of $61.62M is the 2nd highest of the 7 companies compared; the peer median is $41.96M.
  • Its year-over-year change of +248.4% is the highest of 7, against a peer median of -20.9%.
  • Over three fiscal years its annual growth of +72.1% compares with a peer median of -2.9%.
TENX Competitors Peer median
Operating Expenses for TENX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SABSSAB Biotherapeutics, Inc.LTM Jun 2026$69.54M +119.3%-2.5%—
TENXTenax Therapeutics, Inc.LTM Mar 2026$61.62M +248.4%+72.1%—
BOLDBoundless Bio, Inc.LTM Mar 2026$59.47M -19.0%+10.3%—
VRCAVerrica Pharmaceuticals Inc.LTM Mar 2026$46.79M -22.8%+14.2%125.9%
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$37.12M -25.8%-3.3%—
NERVMinerva Neurosciences, Inc.LTM Jun 2026$35.14M +117.4%-15.7%—
QTTBQ32 Bio Inc.LTM Mar 2026$32.06M -49.4%-7.4%59.7%
Peer median (excluding TENX) $41.96M-20.9%-2.9%92.8%

Competitors are the stored peer set for TENX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development25.15M5.38M3.23M12.71M32.67M
Selling, General & Admin7.58M5.68M5.01M6.79M23.71M
Operating Expenses32.73M11.05M8.23M19.49M56.39M
Depreciation & Amortization108.98K113.33K8K00
EBITDA(32.36M)(10.93M)(7.68M)(17.58M)(52.6M)
EBITDA Margin—————
Operating Income(32.73M)(11.05M)(8.23M)(19.49M)(56.39M)
Operating Margin—————
Interest Income0001.91M3.82M
Interest Expense9494.44K23.97K23K0
Other Income / Expenses253.88K4.75K523K1.89M3.79M
Income Before Tax(32.47M)(11.05M)(7.71M)(17.6M)(52.6M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(32.47M)(11.05M)(7.71M)(17.6M)(52.6M)
Net Margin—————
EPS (Basic)(2,524.80)(600.80)(31.09)(1.15)(1.34)
EPS (Diluted)(2,524.80)(600.80)(31.04)(1.15)(1.34)
Weighted Avg Shares12.86K18.39K248K15.27M39.22M
Weighted Avg Shares (Diluted)12.86K18.39K248.45K15.27M39.22M

Tenax Therapeutics, Inc.

NASDAQ:TENX

Intrinsic Alpha fair value

Locked

Current Price

$1.91

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.